Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.51 |
| ▸ | PPID | Q08752 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2039557 | 0.96 | FOLH1 (0.56) | FOLH1PPIDALDH1A1LMNAITGB3 | |
| SCHEMBL16270312 | 0.86 | PPID (0.69) | PPID | |
| SCHEMBL12643652 | 0.86 | PPID (0.69) | PPID | |
| SCHEMBL12643638 | 0.83 | PPID (0.57) | PPIDITGB3ITGAV | |
| SCHEMBL12643966 | 0.83 | PPID (0.68) | FOLH1PPIDITGB3ITGAV | |
| SCHEMBL12643632 | 0.83 | PPID (0.68) | FOLH1PPIDITGB3ITGAV | |
| SCHEMBL2036189 | 0.80 | CA1 (0.48) | FOLH1ALDH1A1LMNAITGB3ITGAV | |
| SCHEMBL4600004 | 0.75 | CPB2 (0.53) | FOLH1ALDH1A1LMNA | |
| SCHEMBL4599998 | 0.75 | CPB2 (0.53) | FOLH1ALDH1A1LMNA | |
| SCHEMBL22299972 | 0.75 | ALB (0.54) | FOLH1ALDH1A1ITGB3ITGAVALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516387-B1 | INHIBITORS OF CYCLOPHILINS FOR USE IN THE PREVENTION AND/OR THE TREATMENT OF VIRAL PATHOLOGIES OR INFECTIONS | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE (INSERM) (FR) | 2018-02-21 | — | — | EP | disclosed |
| US-8901295-B2 | Inhibitors of cyclophilins and uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-12-02 | — | — | US | disclosed |
| US-8802666-B2 | Inhibitors of cyclophilins and uses thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-06-26 | — | — | US | disclosed |
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2013-01-17 | — | — | US | disclosed |
| EP-2516387-A2 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076784-A2 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179687-A1 | New Inhibitors of Cyclophilins and Uses Thereof | FKBP3, FKBP4, FKBP5 | FOLH1 3330/4885PPID 73/4885ALDH1A1 3684/4885 |
| US-20130018044-A1 | NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF | FKBP3, FKBP4, FKBP5 | FOLH1 3330/4885PPID 73/4885ALDH1A1 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.